欧洲胸外科医师学会修订版肺癌分期指南在肺癌患者中的有效性验证
本研究纳入571例潜在可切除的非小细胞肺癌患者,评估欧洲胸外科医师学会(ESTS)修订版术前淋巴结分期指南的有效性。术前经颈部纵隔镜或纵隔镜淋巴结清扫进行纵隔分期,结果显示指南的敏感性95.0%、特异性100%、阳性预测值100%、阴性预测值94.6%、准确率97.2%,表明该指南有效且可行。
要点
- ESTS修订版术前淋巴结分期指南在潜在可切除NSCLC患者中敏感性95.0%、特异性100%。
- 指南的阳性预测值100%、阴性预测值94.6%、准确率97.2%。
- 该指南可能为切除术后的患者提供高生存率。
核心结论
- ESTS修订版术前淋巴结分期指南对潜在可切除NSCLC患者有效且可行,可能提供切除术后高生存。
研究设计与样本
- 术前纵隔分期采用视频辅助颈部纵隔镜或视频辅助纵隔镜淋巴结清扫,除外周围型cT1N0非腺癌患者。
- 无纵隔淋巴结转移者接受开胸或视频辅助胸腔镜切除术,手术病理结果与ESTS指南比较以验证有效性。
主要发现
- 术前发现纵隔淋巴结转移266例(46.6%)。
- 305例患者接受了解剖性肺切除术。
- 指南的敏感性95.0%、特异性100%、阳性预测值100%、阴性预测值94.6%、准确率97.2%。
关键数值与推荐
- ESTS修订版指南的敏感性为95.0%,特异性为100%,阳性预测值为100%,阴性预测值为94.6%,准确率为97.2%。
临床怎么用
- 对于潜在可切除NSCLC患者,可按ESTS修订版指南进行术前纵隔淋巴结分期,以筛选适合直接手术的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The European Society of Thoracic Surgeons (ESTS) has proposed a revised preoperative lymph node staging guideline for patients with potentially resectable non-small cell lung cancer (NSCLC). We aimed to assess the validity of this revised ESTS guideline and survival results in our patient cohort. METHODS: A total of 571 patients with potentially resectable NSCLC seen between January 2004 and November 2013 were included in the study. The preoperative mediastinal staging was performed by video-assisted cervical mediastinoscopy or video-assisted mediastinoscopic lymphadenectomy in all patients except those with peripheral cT1N0 nonadenocarcinoma tumors. Resection via thoracotomy or video-assisted thoracoscopic surgery was done in patients with no mediastinal lymph node metastasis. Surgical pathological results were compared with the ESTS staging guideline, and the validity of the guideline was tested. RESULTS: In this series, mediastinal lymph node metastasis was revealed preoperatively in 266 patients (46.6%). A total of 305 patients underwent anatomic lung resection. The sensitivity, specificity, positive and negative predictive values, and accuracy of the guidelines were calculated as 95.0%, 100%, 100%, 94.6%, and 97.2%, respectively. CONCLUSIONS: The ESTS revised preoperative lymph node staging guidelines for patients with NSCLC seem to be effective and valid, and may provide high survival following resectional surgery.
引用
- Turna A, Melek H, Kara HV, et al. Validity of the updated European Society of Thoracic Surgeons staging guideline in lung cancer patients. J Thorac Cardiovasc Surg. 2017. PMID: 29110950. doi:10.1016/j.jtcvs.2017.09.090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。